Gadoteridol (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Gadoteridol" in English language version.

refsWebsite

Global rank English rank

4^th place

4^th place

447^th place

338^th place

1,712^th place

1,063^rd place

2^nd place

2^nd place

canada.ca

health-products.canada.ca

"Prohance Product information". Health Canada. 30 July 1998. Retrieved 19 April 2024.

doi.org

Morgan DE, Spann JS, Lockhart ME, Winningham B, Bolus DN (April 2011). "Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients". Radiology. 259 (1): 109–16. doi:10.1148/radiol.10100906. PMID 21248237. Specifically, the rate of nausea (0.530%) was less than half the rate (1.4%) in clinical trials of 1251 patients, leading to FDA approval in 1992.

fda.gov

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

nih.gov

dailymed.nlm.nih.gov

Bracco Diagnostic Inc. (26 October 2022). "Gadoteridol (ProHance) prescribing information". DailyMed. U.S. National Library of Medicine. Retrieved 17 May 2023.

pubmed.ncbi.nlm.nih.gov

Morgan DE, Spann JS, Lockhart ME, Winningham B, Bolus DN (April 2011). "Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients". Radiology. 259 (1): 109–16. doi:10.1148/radiol.10100906. PMID 21248237. Specifically, the rate of nausea (0.530%) was less than half the rate (1.4%) in clinical trials of 1251 patients, leading to FDA approval in 1992.